DAPT and GPVI: an antiplatelet triple threat

J Thromb Haemost. 2023 Nov;21(11):3082-3084. doi: 10.1016/j.jtha.2023.08.005.

Authors

Andrew Rickenberg¹, Michael Holinstat²

Affiliations

¹ Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
² Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA; Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA. Electronic address: mholinst@umich.edu.

PMID: 37858525
DOI: 10.1016/j.jtha.2023.08.005

No abstract available

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Aspirin / therapeutic use
Drug Therapy, Combination
Hemorrhage / drug therapy
Humans
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors* / adverse effects
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Aspirin

Grants and funding

R35 GM131835/GM/NIGMS NIH HHS/United States